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In cancer surgery there is a great need for imaging techniques to enable fast, in situ and
accurate characterization of tissue so as to optimize resection. Nowhere is this more critical
than in tumors that arise from the brain parenchyma. Analytical tools such as microscopy
and fluoroscopy, magnetic resonance imaging, and computed tomography have been
increasingly applied to the detection and delineation of human cancerous tissue.[1] While
each method significantly increases the ability to detect tumor and its relationship to
surrounding healthy tissue, limited chemical information, low-sensitivity and the need for
systemic administration of contrast agents are limitations. Mass spectrometry (MS) is a
powerful analytical technique with the potential to play such a role in tumor detection and
diagnosis by imaging the distribution of proteins, lipids and other specific compounds in
tissue.[2,3] Amongst the MS imaging methods, the newer ambient ionization techniques
allow the direct analysis of samples in the open atmosphere.[4] In particular, desorption
electrospray ionization mass spectrometry (DESI-MS) has the advantages of little or no
sample preparation, ease of implementation and high quality analytical data.[5] DESI-MS
imaging has been shown to provide 3D images of lipid distributions in mouse brain[6], to
provide images of antifungals in algae[7], and to distinguish between cancerous and non-
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cancerous canine bladder tissue samples using multiple marker lipids[2]. However, little
work has been reported on human tissue, a notable exception being the observation of
distinctive lipid markers associated with tumor and non-tumor regions in human liver
adenocarcinoma tissue sections.[8] A well-defined tumor margin boundary correlated with
histopathological examination. Related ambient ionization methods have been used for
similar purposes including 3D tissue imaging[9] and for characterization of lipids in surgical
smoke during animal surgery[10].
The World Health Organization (WHO) recognizes over 125 types of brain tumors
according to histopathological evaluation, and classifies them according to cellular
characteristics, and grades malignancy according to proliferation, cellular and nuclear
morphology, vascularization, and a few biomarkers.[11] Gliomas are the most common
human primary brain tumors, with astrocytomas comprising the most common subtype
ranging in grade from WHO grade II to the most aggressive form glioblastoma (WHO grade
IV). Currently, diagnosis and grading of gliomas relies primarily on neuropathological
examination of a biopsy sample and characteristic cytogenetic aberrations.[12] However, the
histopathological examination of frozen specimens for diagnosis or tumor boundary
assessment during surgery is of limited utility in guiding surgical resection as it depends on
expert evaluation of the tissue resected from locations of interest, significantly delaying
surgical intervention. Surgical pathology based approaches therefore need to be
complemented by improved intraoperative diagnosis of tumors and their margins without
interfering with the surgical workflow. MS based molecular evaluation of tissue can rapidly
provide extensive chemical information from biopsy samples, which could aid
differentiation of brain tumors from healthy and functional brain.
Here, we report on the use of DESI-MS to analyze and characterize the lipid profiles of
different grades of human astrocytomas. Lipids make up a major portion of brain tissue and
altered levels of lipids in brain tissue are associated with several diseases.[13,14]
Specifically, altered lipid compositions as determined by classical extraction methods have
been reported in human gliomas.[15] The lipid composition of a cell reflects its histological
cell type, state of cellular growth, maturation and differentiation. Therefore, the lipid
composition of tissues could provide valuable information in terms of disease diagnosis.[16]
Herein, the sphingo and glycerophospholipid compositions of astrocytoma tumor samples
were investigated, and distinct lipid profiles concordant with WHO grade were observed.
These results show that differentiation of grade within this type of human brain cancer can
be achieved by direct DESI-MS analysis of tissue with the lipid constituents providing the
needed information.
Glioma specimens from seven human subjects were examined using DESI-MS in the
negative and positive ion modes. Patients gave informed consent for tissue review in
accordance with the Internal Review Board of Partners Healthcare, and tissue samples were
handled in accordance with institutional guidelines. From the seven biopsy samples
evaluated by an expert neuropathologist (K.L.), one was diagnosed as a diffuse astrocytoma
(WHO grade II), two were diagnosed as anaplastic astrocytoma (WHO grade III), and four
as glioblastoma (GBM) (WHO grade IV), from which three showed epidermal growth factor
receptor (EGFR) amplification. Identical standard DESI-MS imaging conditions were used
to analyze the tissue specimens, and serial sections were independently analyzed in a second
laboratory, the results of which were in qualitative agreement with those reported herein (see
the Supporting Information and Figure S4 for experimental details). Lipid assignments were
confirmed by tandem mass spectrometry (MS/MS) experiments compared to existing ESI
product-ion mass spectra in the literature. [17]
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The major ions observed in the negative mode correspond to four main lipid classes;
glycerophosphoinositols (PI), glycerophosphoserines (PS), plasmenyl glycerophospho
ethanolamines (plasmenyl-PE), and sulfatides (ST). In the positive ion mode, the major ions
observed correspond to three main lipid classes; glycerophosphocholines (PC),
sphingomyelins (SM) and galactoceramides (GalCer). Each DESI-MS image represents the
abundance of ions of one particular value of mass-to-charge ratio (m/z) and consequently
shows the distribution of the corresponding molecule in the tissue sample.
A representative mass spectrum (m/z 650 to 1000) of a tissue specimen collected from a
subject diagnosed with diffuse astrocytoma (WHO grade II) is shown in Figure 1a. The
major ions observed in the mass spectrum correspond to lipids of classes ST, PS and PI, and
are identified as follows; m/z 788.2, PS(36:1); m/z 806.5, ST(h18:0); m/z 885.4, PI(38:4); m/
z 888.6, ST(24:1); m/z 890.5, ST(24:0); m/z 904.6, ST(h24:1); m/z 906.6, ST(h24:0); and m/z
916.6, ST(26:1). Table S1, Supporting Information, lists the major peaks detected in the
human glioma tissue in the negative ion mode. Figure 1c shows a representative negative ion
mode mass spectrum obtained from sample G5, a case of grade IV astrocytoma (GBM). In
contrast with the grade II tumor, the highest ion abundances detected in this higher grade of
astrocytoma in the negative ion mode correspond to lipids of the classes PS, PI and
plasmenyl-PE. The most abundant ions are identified as follows; m/z 750.3 plasmenyl-
PE(38:4); m/z 788.2, PS(36:1); m/z 810.2, PS(38:4); m/z 812.2, PS(38:3); m/z 834.2,
PS(40:6); m/z 836.2, PS(40:5); m/z 838.2; PS(40:4); m/z 885.3, PI(38:4); and m/z 887.3,
PI(38:3). Negative ion mode mass spectra obtained for other GBM samples (G6, G7 and
G8) are shown in Figure S1. The same lipid composition was observed for each of the
samples of GBM, with the lipids PS(40:6), PI(38:4) and PS(36:1) giving the most abundant
ions in all the samples analyzed. Note that the sulfatide ions observed for the diffuse
astrocytoma are completely absent in the GBM tissues analyzed. While the lipid profiles
observed for grade II and grade IV astrocytomas are distinct, the negative ion mode mass
spectrum obtained from sample G4, a case of anaplastic astrocytoma (WHO grade III),
Figure 1b, presents a transitional lipid composition, showing the presence of the sulfatide
ions observed in the grade II sample, as well as an increased abundance of
glycerophosphoserine peaks characteristic of the GBM lipid profile.
Similar trends in tissue lipid profiles with increasing malignancy were observed in the
positive ion mode spectra. Figures 2 a, b and c show representative spectra obtained for the
samples G2 (grade II), G4 (grade III), and G5 (GBM, grade IV), respectively. For the
different grades of astrocytomas, the main positive ions observed are sodium and potassium
adducts of glycerophosphocholines. The main ions observed are m/z 782.6, identified as
PC(34:1)+Na+, m/z 798.4, identified as PC(34:1)+K+ and m/z 756.6, identified as
PC(32:0)+Na+. However, a series of ions identified as galactoceramides was observed most
abundantly in the positive mode spectrum for sample G2, grade II astrocytoma and in lower
abundance in the spectrum obtained for sample G4, grade III astrocytoma. These
galactoceramide ions are absent in the spectra obtained from all four glioblastoma samples
(G5-G8) (Figure S2). Figure S3 shows the product ion spectrum generated from tandem MS
experiments on m/z 850.6, identified as a sodium adduct of GalCer(d18:1/24:0h). The
fragmentation pattern of this ion is consistent with the molecular structure and is consistent
with reported literature.[18] Table S2, Supporting Information, summarizes the
identification of the major peaks detected in the glioma samples in the positive ion mode.
Technical reproducibility was assessed by analyzing different tissue sections of the same
sample on different days under the same experimental conditions (Figure S5, Supporting
Information).
DESI-MS molecular images obtained for the main ions observed in the negative ion mode
are shown in Figure 3 a-e for samples of grade II, III, and IV respectively. Standard
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histological hematoxylin and eosin (H&E) staining was performed on serial sections and
corresponding optical images are shown in Figure 3f. The differences in lipid composition
observed in the negative mode are clearly observed in the DESI-MS ion images obtained for
the samples analyzed. Comparison between the ion images of the different samples clearly
demonstrate the change in lipid composition as a function of the astrocytoma grade.
Our findings indicate that it is possible to establish three different lipid profiles
corresponding to each degree of malignancy II, III, and IV in astrocytic tumors by negative
and positive ion DESI-MS analysis although examination of a larger number of samples is
needed to confirm these findings. Indeed, the concurrent change in lipid composition with
astrocytoma grade observed with a combination of the negative and positive ion modes
corroborates previous reports based on classical lipid extraction methodologies.[19] It has
been observed that as the malignancy of astrocytomas increases, there is a decreased
abundance of sulfatides and galactoceramides.[16] It has also been reported that while
galactosylcerebrosides and sulfatides are absent from glioblastoma, they are present in
astrocytomas grade II.[20] Since these distinctive lipids profiles are easily assessed using
DESI-MS imaging, this technique has the potential to be utilized for differentiating human
astrocytomas directly from tissue.
The approach reported here supports the feasibility of using lipid profiles for the
differentiation of astrocytoma grades using DESI-MS. Moreover, the results are validated by
previous reports on the characterization of lipids from gliomas, each involving initial lipid
extraction followed by either HPLC or HPTLC separation.[16,19,20] A follow up biomarker
discovery phase will require increasing the sample size to derive and validate classification
models. Multiple sampling sites with varying tumor cell density would also contribute to
minimizing the effect of a lack of true non-tumor controls inherent to the study of brain
diseases. Because DESI-MS is an ambient technique with a characteristic ease and rapidity
of execution, the approach might possibly translate to in situ analysis of gliomas to assist in
intraoperative surgical decision making.
Supplementary Material
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Figure 1.
Representative negative ion mode DESI spectra of human tumor tissues. a) Sample G2,
diffuse astrocytoma (WHO grade II), b) sample G4, anaplastic astrocytoma (WHO grade III)
and c) sample G5, glioblastoma (WHO grade IV). See text for lipid abbreviations.
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Figure 2.
Representative positive ion mode DESI spectra of human tumor tissues. a) Sample G2,
diffuse astrocytoma (WHO grade II), b) sample G4, anaplastic astrocytoma (WHO grade III)
and c) sample G5, glioblastoma (WHO grade IV). See text for lipid abbreviations.
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Figure 3.
Selected negative ion DESI-MS images from three of the different glioma samples analyzed,
sample G2 (diffuse astrocytoma WHO grade II), sample G4 (anaplastic astrocytoma WHO
grade III) and sample G5 (glioblastoma, astrocytom a WHO grade IV), showing the
distribution of a) m/z 788.8 (PS 36:1), b) m/z 834.2 (PS 40:6), c) m/z 885.4 (PI 38:4), d) m/z
888.4 (ST 24:1), e) m/z 916.5 (ST 26:1). Optical images of the stained tissue sections are
shown in f).
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